Skip to content
Company Analysis

Embecta Corp. EMBC

A comprehensive view of key metrics, scores, and financial health for Embecta Corp.

Overview of Embecta Corp.

EMBC NMS
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Micro Cap
Embecta Corp. (EMBC), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $3.10, about 936.8% undervalued vs fair value, -67.6% 1Y return, placing in the top 25% of its sector.
Metrics P/E 8.7× Rev Growth -3.8% ROE -13.7% Gross Margin 62.6% Div Yield 4.24%
USD 3.10
0.65%
(Delayed)
• Vol 90d: 151.5%
52-Week Range
Market Cap
$182.73M
Enterprise Value
$1.38B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 87%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.embecta.com
HQ Parsippany, NJ
Employees 1,850
Fiscal year Sep 30

Next Events

Dividend Jun 15
Earnings Aug 6 Estimated

Fair Value Snapshot

Bear Base Bull
$29
$32
$36
Current: $3.10 +937% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.1B
-3.8%%
Gross Profit
$676.8M
-7.9%%
Operating Income (GAAP)
$296.4M
4%%
EBITDA
$284.3M
47.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
62.6%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$40.7M
22.3% of Free Cash Flow

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
5
Active Leaks
4/5
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Embecta Corp.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
69
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
66
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing EMBC's balance between Growth (17.9%), Profitability (48.1%), and Safety (34.1%). Growth 18% Safety 34% Profitability 48%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

30th percentile vs peers
31
Key Signals
EPS Growth YoY 20.6% 49p Rev Growth YoY -3.8% 23p Revenue CAGR 3Y -1.5% 26p TSR 4.3% 53p EPS CAGR 3Y -25.3% 13p
Strengths
  • FCF Margin in top 20% of peers (16.9%, 89th percentile)
  • Operating Margin in top 20% of peers (27.4%, 95th percentile)
  • ROIC in top 20% of peers (27.8%, 94th percentile)
  • Operating Cash Flow Margin in top 20% of peers (17.7%, 82th percentile)
Risks
  • Growth below peer median (percentile: 30)

Profitability

82th percentile vs peers
83
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

58th percentile vs peers
59
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Embecta Corp..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$32.14
- - -
+936.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000